N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma
AbstractBackground. Patients with glioblastoma without O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation are unlikely to benefit from alk
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[January 2019]
|
| In: |
Neuro-Oncology
Year: 2018, Jahrgang: 21, Heft: 1, Pages: 95-105 |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/noy161 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1093/neuonc/noy161 Verlag, Volltext: https://academic.oup.com/neuro-oncology/article/21/1/95/5113425 |
| Verfasserangaben: | Wolfgang Wick, Susan Dettmer, Anne Berberich, Tobias Kessler, Irini Karapanagiotou-Schenkel, Antje Wick, Frank Winkler, Elke Pfaff, Benedikt Brors, Jürgen Debus, Andreas Unterberg, Martin Bendszus, Christel Herold-Mende, Andreas Eisenmenger, Andreas von Deimling, David T.W. Jones, Stefan M. Pfister, Felix Sahm, and Michael Platten |
| Zusammenfassung: | AbstractBackground. Patients with glioblastoma without O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation are unlikely to benefit from alk |
|---|---|
| Beschreibung: | Published: 01 October 2018 Im Titel ist die Ziffer 2 hochgestellt Gesehen am 26.06.2019 |
| Beschreibung: | Online Resource |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/noy161 |